Becton, Dickinson and Company (NYSE:BDX – Get Free Report) and Organigram Global (NASDAQ:OGI – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
Volatility & Risk
Becton, Dickinson and Company has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
Institutional & Insider Ownership
87.0% of Becton, Dickinson and Company shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 0.4% of Becton, Dickinson and Company shares are owned by company insiders. Comparatively, 0.1% of Organigram Global shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Becton, Dickinson and Company and Organigram Global’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Becton, Dickinson and Company | 5.66% | 14.90% | 7.09% |
| Organigram Global | 28.14% | -13.39% | -8.67% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Becton, Dickinson and Company and Organigram Global, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Becton, Dickinson and Company | 1 | 9 | 8 | 0 | 2.39 |
| Organigram Global | 1 | 0 | 2 | 0 | 2.33 |
Becton, Dickinson and Company currently has a consensus target price of $197.47, indicating a potential downside of 6.94%. Given Becton, Dickinson and Company’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Becton, Dickinson and Company is more favorable than Organigram Global.
Valuation & Earnings
This table compares Becton, Dickinson and Company and Organigram Global”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Becton, Dickinson and Company | $19.46 billion | 3.00 | $1.15 billion | $4.14 | 51.25 |
| Organigram Global | $185.07 million | 0.44 | -$17.70 million | $0.46 | 1.27 |
Becton, Dickinson and Company has higher revenue and earnings than Organigram Global. Organigram Global is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.
Summary
Becton, Dickinson and Company beats Organigram Global on 11 of the 13 factors compared between the two stocks.
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.
About Organigram Global
Organigram Global Inc. is a Canadian cannabis company that cultivates, processes and sells cannabis and cannabinoid products. Its offerings include dried flower, pre-rolls, edibles, vape products, concentrates and cannabis-infused beverages, sold under brands such as Edison, SHRED, Big Bag O’ Buds and BOXHOT. The company traces its roots to Organigram, a licensed cannabis producer established in New Brunswick. It expanded its portfolio and manufacturing capabilities through acquisitions, including the 2024 purchase of Canadian cannabis company Motif Labs.
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
